MÉDECINS SANS FRONTIÈRES
With €300,000, the Jung Foundation is supporting the “endTB-Q” study conducted by Médecins Sans Frontières. The study aims to improve treatment for people in need suffering from drug-resistant tuberculosis. Initial results from this groundbreaking Phase III project have now been published: At its core is an innovative, personalized therapy that, for the first time, combines the highly effective drugs Bedaquilin, Clofazimine, Delamanid, and Linezolid (BCDL). The study demonstrates that this shorter and less burdensome treatment method achieves high cure rates, particularly in patients without severe TB at the start of therapy.
With these results, the project, funded by the Jung Foundation, sets new standards in the fight against drug-resistant tuberculosis and offers promising perspectives for global healthcare. The project will run until the end of 2025. The full press release on the preliminary results can be found here.